关于我们
With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD. For more information, please visit https://aeglea.com.
- 网站
-
https://www.aeglea.com
Aeglea BioTherapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Austin，Texas
- 类型
- 上市公司
- 创立
- 2013
- 领域
- biotech、biotechnology、rare disease、human enzymes和engineering enzymes
地点
-
主要
获取路线
805 Las Cimas Pkwy
Suite 100
US，Texas，Austin，78746